Trial · NCT05691257
Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
NCT05691257, Phase 4, Unknown, China-Japan Friendship Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia. Trials, record NCT05691257. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05691257
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia
- NCT number
- NCT05691257
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 300 participants, estimated
- Lead sponsor
- China-Japan Friendship Hospital
- Conditions
- Heart Failure, Chronic Kidney Diseases, Anemia
- Interventions
- Roxadustat, Recombinant human eythropoietin and/or Iron agents
- First posted
- 2023-01-19
- Last updated
- 2023-01-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the hemoglobin from baseline | up to 8 week | Hemoglobin is calculated by the routine blood test |
| Secondary | Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) | Up to 8 weeks | Change from baseline to week 12 in N-terminal pro-brain natriuretic peptide (NT-proBNP). Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Left Ventricular Systolic Function | Up to 24 weeks | Change in left ventricular ejection fraction is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left Ventricular End-Diastolic Diameter | Up to 24 weeks | Change in left ventricular end-diastolic diameter is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left Ventricular Diastolic Function | Up to 24 weeks | Change in E/e' is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Low-density lipoprotein（LDL） | Up to 8 weeks | Change from baseline to week 8 in Low-density lipoprotein（LDL）.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Serum ferritin | Up to 8 weeks | Change from baseline to week 8 in Serum ferritin.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Transferrin saturation | Up to 8 weeks | Change from baseline to week 8 in Transferrin saturation.Baseline value was defined as the mean of all available measurements from the screening visit until start of treatment with randomised study medication. |
| Secondary | Change in Left atrial volume | Up to 24 weeks | Change in left atrial volume is assessed by two-dimensional directed M-mode echocardiography |
| Secondary | Change in Left atrial volume index | Up to 24 weeks | Change in left atrial volume index is assessed by two-dimensional directed M-mode echocardiography |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05691257
GET https://conductscience.org/api/trials/v1/NCT05691257/registered